Teplizumab

Teplizumab is a medication designed to delay the onset of type 1 diabetes in people at high risk of developing the disease. It works by targeting and modifying the immune system, specifically to prevent it from attacking insulin-producing cells in the pancreas. This approach can help preserve the body’s ability to produce insulin longer than without treatment. Teplizumab is usually administered as an infusion and is considered an innovative therapy in diabetes care, offering hope for those predisposed to this autoimmune condition. It received FDA approval for use in 2022.